The World Health Organization (WHO), together with HRP (the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction) are hosting a Global pre‑eclampsia summit, a multi‑stakeholder convening designed to accelerate progress on preventing, diagnosing, and treating pre‑eclampsia worldwide, which accounts for 16% of maternal deaths and half a million fetal and newborn deaths worldwide every year.
Bringing together researchers, policymakers, funders, clinicians, product developers, advocates and global health agencies, the Summit will serve as a catalytic platform to align priorities, unlock innovation and drive coordinated action across the full continuum from discovery science to market access and country implementation.
Participants will collectively review persistent gaps in research, clinical guidance, access to essential health products and implementation and scale up, with a particular focus on overcoming the disproportionately high burden of maternal and newborn deaths in low‑ and middle‑income countries. Through expert deliberation, evidence synthesis and structured priority‑setting, the Summit aims to generate a shared vision for the future of pre‑eclampsia care and reshape global efforts through 2030 and beyond.
Outcomes
By the end of the Summit, participants will have:
- Identified and prioritized critical research, normative, access-to-health-products, implementation and advocacy gaps for hypertensive disorders of pregnancy;
- Reviewed the current pipeline of diagnostics, medicines, and interventions for hypertensive disorders of pregnancy and define pathways to policy change and implementation at scale;
- Identified priority access-to-health-product barriers and market-shaping actions, including regulatory, manufacturing, pricing, procurement, supply chain, and quality-assurance strategies, to enable timely, equitable, and sustainable access to essential and innovative pre-eclampsia and eclampsia commodities in LMICs; and
- Agreed on a coordinated Global Roadmap and Call to Action to guide investments, research, policy, implementation, and advocacy efforts related to hypertensive disorders of pregnancy through 2030 and beyond.